# Hour 20 PSL Scores: 20:00-20:59

Released on 23 March 2026 | CEO Kevin Kawchak | ChemicalQDevice

## PSL Scores at End of Hour 20

| Robot Type | Dim A (Omniscient) | Dim B (Omnipresent) | Dim C (Omnipotent) | PSL | Delta | Band |
|-----------|-------------------|--------------------|--------------------|-----|-------|------|
| Surgical Robots | 7.8 | 6.4 | 8.0 | 7.4 | 0.0 | Advanced |
| Cobots | 7.4 | 6.9 | 6.8 | 7.0 | 0.0 | Advanced |
| RT Positioning | 7.9 | 6.4 | 7.3 | 7.2 | 0.0 | Advanced |
| Needle-Placement | 7.2 | 5.9 | 6.9 | 6.7 | 0.0 | Advanced |
| Social Companion | 5.9 | 7.6 | 4.4 | 6.0 | 0.0 | Intermediate |
| Humanoids | 6.2 | 6.4 | 5.6 | 6.1 | 0.0 | Intermediate |
| RT Motion-Tracking | 8.2 | 6.6 | 7.4 | 7.4 | 0.0 | Advanced |
| Imaging Assistant | 7.4 | 7.2 | 6.2 | 6.9 | 0.0 | Advanced |
| Steerable Needle | 7.6 | 5.6 | 7.4 | 6.9 | 0.0 | Advanced |
| Rehab Exoskeletons | 5.9 | 6.2 | 5.9 | 6.0 | 0.0 | Intermediate |

## Cumulative Site PSL: 65.6 (Advanced Site) - No Change

## Scoring Changes This Hour

### No PSL Changes This Hour

All robot types maintain their existing PSL scores. Justification by active
robot type:

- Surgical Robots: SURG-01 continues an ongoing procedure for PAT-ODMND-0154
  from Hour 19 with nominal performance. Surgery is progressing without
  complications and robot telemetry is within all specifications. No new
  capability demonstrated beyond existing score baseline. No change.

- Cobots: COBOT-03 performed a routine US-guided core needle biopsy for
  PAT-ODMND-0163 with 0.4 mm trajectory accuracy and 4 Grade A cores. This
  is consistent with established cobot performance (prior hours demonstrated
  similar accuracy and sample quality). No change warranted per PSL scoring
  criteria (Kawchak, 2026; DOI: 10.5281/zenodo.18778220).

- RT Positioning: RTPOS-02 completed an SRS mask fitting and CT simulation
  for PAT-ODMND-0164 (GBM, Stage IV) with 96.8% mask conformity and 0.5 mm
  positioning accuracy. Performance is within the established envelope for
  this robot type and consistent with current PSL 7.2. AI lesion detection
  correctly identified the primary GBM and perilesional edema but did not
  demonstrate capability beyond what was previously scored. No change.

- RT Motion-Tracking: TRACK-02 delivered fraction 3 of 5 for PAT-ODMND-0162
  (NSCLC IIIB) with 0.6 mm fiducial tracking accuracy and 94.2% gating
  efficiency. Dose delivery was 100.0% of prescription with all OAR
  constraints met. This performance is consistent with the existing PSL 7.4.
  No new capability or edge-case handling demonstrated. No change.

- Imaging Assistant: IMAGE-03 completed a contrast-enhanced CT with AI
  volumetric analysis for PAT-ODMND-0165 (HCC) achieving LI-RADS 5
  classification with 94-second processing time. IMAGE-04 initiated imaging
  for PAT-ODMND-0166 (liver metastases) but the procedure extends into
  Hour 21. The IMAGE-03 performance is consistent with existing PSL 6.9.
  No change.

- All other robot types (Needle-Placement, Social Companion, Humanoids,
  Steerable Needle, Rehab Exoskeletons): No activity this hour. Scores
  unchanged.

## Site PSL Trend (Selected Hours)

| Hour | Site PSL | Delta | Key Driver |
|------|----------|-------|-----------|
| 00 | 63.4 | - | Baseline |
| 04 | 63.6 | +0.1 | Surgical robot calibration improvement |
| 08 | 64.0 | +0.2 | Morning ramp-up, multi-robot coordination |
| 12 | 64.8 | +0.2 | Peak volume performance validation |
| 16 | 65.4 | +0.2 | Afternoon complex cases |
| 18 | 65.6 | +0.1 | Evening procedure efficiency gains |
| 19 | 65.6 | 0.0 | Standard evening operations |
| 20 | 65.6 | 0.0 | Wind-down period, no new capabilities |

## USL Comparison Note

The USL framework (Kawchak, 2026; DOI: 10.5281/zenodo.18778220) evaluates
robot technical interoperability. Key USL scores for reference:

| Robot Platform | USL Score | PSL Score (this sim) |
|---------------|-----------|---------------------|
| da Vinci dVRK | 7.1 | 7.4 (Surgical) |
| Franka Panda | 7.4 | 7.0 (Cobot) |
| Boston Dynamics Atlas | 5.8 | 6.1 (Humanoid) |

During the wind-down period, robot utilization drops to approximately 30%
as the facility transitions from peak evening operations toward overnight
low-volume mode. The stable PSL scores during reduced utilization reflect
the maturity of the robot platforms and the consistency of their performance
across varying workload conditions. No PSL regression is observed during
low-utilization periods, supporting the stability of the omniscient,
omnipresent, and omnipotent scoring dimensions under the PSL framework.

PSL and USL measure different aspects: USL focuses on technical unification
readiness while PSL focuses on clinical trial performance (omniscience,
omnipresence, omnipotence) in the context of physical AI oncology care
delivery per 21 CFR Part 820 quality system requirements and IEC 62304
software lifecycle standards.
